| Sitemap | / |
Always consult with a
veterinarian that you feel
comfortable with before
diagnosing or treating any
disease on your own.
This area is for
reference only.
Health Issues
|
|
Canine Parvovirus
Issue Description
Is a contagious virus mainly affecting dogs. The disease is highly infectious and is spread from dog to dog by direct or indirect contact with their feces. It can be especially severe in puppies that are not protected by maternal antibodies or vaccination. It has two distinct presentations, a cardiac and intestinal form. The common signs of the intestinal form are severe vomiting and severe haemmorhagic (bloody) diarrhea. The cardiac form causes respiratory or cardiovascular failure in young puppies. Treatment often involves veterinary hospitalization. Vaccines can prevent this infection, but mortality can reach 91% in untreated cases.
There are two types of canine parvovirus called canine minute virus (CPV1) and CPV2. CPV2 causes the most serious disease and affects domesticated dogs and wild canids. There are variants of CPV2 called CPV-2a, CPV-2b and CPV-2c. Types 2a and 2b are distinct from the original CPV type 2 in terms of virulence and their ability to infect and cause disease in cats too. CPV-2c is a newly identified variant similar to 2b. The viral protein of 2c contains one amino acid different from CPV-2b but it is believed this could be significant. 2c strains have been identified in parts of Europe, the Americas and in Asia. Emergence of this strain has led to claims of ineffective vaccination of dogs, however studies have shown that the existing CPV vaccines still provide adequate levels of protection against CPV type 2c.
Is a contagious virus mainly affecting dogs. The disease is highly infectious and is spread from dog to dog by direct or indirect contact with their feces. It can be especially severe in puppies that are not protected by maternal antibodies or vaccination. It has two distinct presentations, a cardiac and intestinal form. The common signs of the intestinal form are severe vomiting and severe haemmorhagic (bloody) diarrhea. The cardiac form causes respiratory or cardiovascular failure in young puppies. Treatment often involves veterinary hospitalization. Vaccines can prevent this infection, but mortality can reach 91% in untreated cases.
There are two types of canine parvovirus called canine minute virus (CPV1) and CPV2. CPV2 causes the most serious disease and affects domesticated dogs and wild canids. There are variants of CPV2 called CPV-2a, CPV-2b and CPV-2c. Types 2a and 2b are distinct from the original CPV type 2 in terms of virulence and their ability to infect and cause disease in cats too. CPV-2c is a newly identified variant similar to 2b. The viral protein of 2c contains one amino acid different from CPV-2b but it is believed this could be significant. 2c strains have been identified in parts of Europe, the Americas and in Asia. Emergence of this strain has led to claims of ineffective vaccination of dogs, however studies have shown that the existing CPV vaccines still provide adequate levels of protection against CPV type 2c.
|
|
Other Names
CPV, Colloquioally Parvo
History
CPV2 is a relatively new disease that appeared in the late 1970s. It was first recognized in 1978 and spread worldwide in one to two years. The virus is very similar to feline panleukopenia (also a parvovirus); they are 98% identical, differing only in two amino acids in the viral capsid protein VP2.[2] It is also highly similar to mink enteritis, and the parvoviruses of raccoons and foxes. The early belief was that the feline panleukopenia mutated into CPV2. Although this has not been proven, the strong similarity to feline panleukopenia makes this the most credible theory. However, it is possible that CPV2 is a mutant of an unidentified parvovirus (similar to feline parvovirus (FPV)) of some wild carnivore. A strain of CPV2b (strain FP84) has been shown to cause disease in a small percentage of domestic cats, although vaccination for FPV seems to be protective. CPV2, however, does not cause disease in cats and does so only mildly in mink and raccoons, and is a virus almost exclusively affecting canines.
Two more strains of canine parvovirus CPV2a and CPV2b were identified in 1979 and 1984 respectively. Most cases of canine parvovirus infection are believed to be caused by these two strains, which have replaced the original strain, and the present day virus is different from the one originally discovered although they are indistinguishable by most routine tests. A third type, CPV2c (a Glu-426 mutant), has been discovered in Italy, Vietnam, and Spain.
Virology
CPV2 is a non-enveloped single-stranded DNA virus. The name comes from the Latin parvus, meaning small, as the virus is only 20 to 26 nm in diameter. It has an icosahedral symmetry.
CPV, Colloquioally Parvo
History
CPV2 is a relatively new disease that appeared in the late 1970s. It was first recognized in 1978 and spread worldwide in one to two years. The virus is very similar to feline panleukopenia (also a parvovirus); they are 98% identical, differing only in two amino acids in the viral capsid protein VP2.[2] It is also highly similar to mink enteritis, and the parvoviruses of raccoons and foxes. The early belief was that the feline panleukopenia mutated into CPV2. Although this has not been proven, the strong similarity to feline panleukopenia makes this the most credible theory. However, it is possible that CPV2 is a mutant of an unidentified parvovirus (similar to feline parvovirus (FPV)) of some wild carnivore. A strain of CPV2b (strain FP84) has been shown to cause disease in a small percentage of domestic cats, although vaccination for FPV seems to be protective. CPV2, however, does not cause disease in cats and does so only mildly in mink and raccoons, and is a virus almost exclusively affecting canines.
Two more strains of canine parvovirus CPV2a and CPV2b were identified in 1979 and 1984 respectively. Most cases of canine parvovirus infection are believed to be caused by these two strains, which have replaced the original strain, and the present day virus is different from the one originally discovered although they are indistinguishable by most routine tests. A third type, CPV2c (a Glu-426 mutant), has been discovered in Italy, Vietnam, and Spain.
Virology
CPV2 is a non-enveloped single-stranded DNA virus. The name comes from the Latin parvus, meaning small, as the virus is only 20 to 26 nm in diameter. It has an icosahedral symmetry.
The genome is about 5000 nucleotides long. CPV2 continues to evolve, and the success of new strains seems to depend on extending the range of
hosts affected and improved binding to its receptor, the canine transferrin receptor. CPV2 has a high rate of evolution, possibly due to a rate of nucleotide
substitution that is more like RNA viruses such as Influenzavirus A. In contrast, FPV seems to evolve only through random genetic drift.
CPV2 affects dogs, wolves, foxes, and other canids. CPV2a and CPV2b have been isolated from a small percentage of symptomatic cats and is more common than feline panleukopenia in big cats.
Previously it has been thought that the virus does not undergo cross species infection. However studies in Vietnam have shown that CPV2 can undergo minor antigenic shift and natural mutation to infect felids. Analyses of feline parvovirus (FPV) isolates in Vietnam and Taiwan revealed that more than 80% of the isolates were of the canine parvovirus type, rather than feline panleukopenia virus (FPLV).[13] CPV2 may spread to cats easier than dogs and undergo faster rates of mutation within that species. The virus does not transmit to birds, or humans , but it can be spread by them when a bird comes in contact with feces and then the dog's environment, or when a cat goes to the groomers and returns with an exposed pet carrier.
Variants
There are variants of CPV type 2 called CPV-2a, CPV-2b and CPV-2c. The antigenic patterns of 2a and 2b are quite similar to the original CPV type 2. Variant 2c however has a unique pattern of antigenicity. This has led to claims of ineffective vaccination of dogs, but studies have shown that the existing CPV vaccines based on CPV type 2b, provide adequate levels of protection against CPV type 2c. However, there are reports that outdated vaccines based on the old CPV-type 2 may not afford sufficient cross-protection against the type 2c variant.
Pathophysiology
There are two forms of CPV2: intestinal and cardiac. Puppies are most susceptible, but more than 80 percent of adult dogs show no symptoms. With severe disease, dogs can die within 48 to 72 hours without treatment by fluids and antibiotics. In the more common, less severe form, mortality is about 10 percent. Certain breeds, such as Rottweilers, Doberman Pinschers, and Pit bull terriers as well as other black and tan colored dogs may be more susceptible to CPV2. Along with age and breed, factors such as a stressful environment, concurrent infections with bacteria, parasites, and canine coronavirus increase a dog's risk of severe infection. Dogs who catch Parvovirus usually die from the dehydration it causes or secondary infection rather than the virus itself.
Intestinal form
Dogs become infected through oral contact with CPV2 in feces, infected soil, or fomites that carry the virus. Following ingestion, the virus replicates in the lymphoid tissue in the throat, and then spreads to the bloodstream. From there, the virus attacks rapidly dividing cells, notably those in the lymph nodes, intestinal crypts, and the bone marrow. There is depletion of lymphocytes in lymph nodes and necrosis and destruction of the intestinal crypts. Anaerobic bacteria that normally reside in the intestines can then cross into the bloodstream, a process known as translocation, and cause sepsis. The most common bacteria involved in severe cases are Clostridia, Campylobacter and salmonellaspecies. This can lead to a syndrome known as Systemic inflammatory response syndrome(SIRS). SIRS leads to a range of complications such as hypercoagulability of the blood, endotoxaemia and acute respiratory distress syndrome(ARDS). Bacterial Myocarditis has also been reported secondarily to sepsis. Dogs with CPV are at risk of intussusception, a condition where part of the intestine prolapses into another part. Three to four days following infection, the virus is shed in the feces for up to three weeks, and the dog may remain an asymptomatic carrier and shed the virus periodically. The virus is usually more deadly when infested with worms or other intestinal parasites.
Cardiac form
This form is less common and affects puppies infected in the uterus or shortly after birth until about 8 weeks of age. The virus attacks the heart muscle and the puppy often dies suddenly or after a brief period of breathing difficulty. On the microscopic level, there are many points of necrosis of the heart muscle that are associated with mononuclear cellular infiltration. The formation of excess fibrous tissue (fibrosis) is often evident in surviving dogs. Myofibers are the site of viral replication within cells. The disease may or may not be accompanied with the signs and symptoms of the intestinal form. However, this form is now rarely seen due to widespread vaccination of breeding dogs.
Even less frequently, the disease may also lead to a generalized infection in neonates and cause lesions and viral replication and attack in other tissues other than the gastrointestinal tissues and heart, but also brain, liver, lungs, kidneys, and adrenal cortex. The lining of the blood vessels are also severely affected, which lead the lesions in this region to hemorrhage.
Infection in the uterus
This type of infection can occur when a pregnant female dog is infected with CPV2. The adult may develop immunity with little or no clinical signs of disease. The virus may have already crossed the placenta to infect the foetus. This can lead to several abnormalities. In severe cases the pups can be still born or born mummified, in mild to moderate cases the pups can be born with neurological abnormalities such as cerebellar hypoplasia.
Signs and symptoms
Dogs that develop the disease show symptoms of the illness within 5 to 10 days. The symptoms include lethargy, vomiting, fever, and diarrhea (usually bloody). Diarrhea and vomiting result in dehydration and secondary infections can set in. Due to dehydration, the dog's electrolyte balance can become critically affected. Because the normal intestinal lining is also compromised, blood and protein leak into the intestines leading to anemia and loss of protein, and endotoxins escaping into the bloodstream, causing endotoxemia. Dogs have a distinctive odor in the later stages of the infection. The white blood cell level falls, further weakening the dog. Any or all of these factors can lead to shock and death.
Diagnosis
Diagnosis is made through detection of CPV2 in the feces by either an EIA or a hemagglutination test, or by electron microscopy. PCR has become available to diagnose CPV2, and can be used later in the disease when potentially less virus is being shed in the feces that may not be detectable by EIA. Clinically, the intestinal form of the infection can sometimes be confused with coronavirus or other forms of enteritis. Parvovirus, however, is more serious and the presence of bloody diarrhea, a low white blood cell count, and necrosis of the intestinal lining also point more towards parvovirus, especially in an unvaccinated dog. The cardiac form is typically easier to diagnose because the symptoms are distinct.
Prevention and decontamination
Prevention is the only way to ensure that a puppy or dog remains healthy since the disease is extremely virulent and contagious. The virus is extremely hardy and has been found to survive in feces and other organic material such as soil for over a year. It survives extremely cold and hot temperatures. The only household disinfectant that kills the virus is bleach.
Weaning puppies can be vaccinated with a modified live virus low passage high titer vaccine at 6 weeks of age, then every 3 to 4 weeks until 15 or 16 weeks. Puppies are initially protected through passive immunity derived from the mother. These maternal antibodies wear off before the puppy's immune system is mature enough to fight off CPV2 infection. Maternal antibodies also interfere with vaccination for CPV2 and can cause vaccine failure. Thus puppies are generally vaccinated in a series of shots, extending from the earliest time that the immunity derived from the mother wears off until after that passive immunity is definitely gone. Older puppies (16 weeks or older) are given 3 vaccinations 3 to 4 weeks apart. The duration of immunity of vaccines for CPV2 has been tested for all major vaccine manufacturers in the United States and has been found to be at least three years after the initial puppy series and a booster 1 year later.
A dog that successfully recovers from CPV2 sheds virus for a few days. Ongoing infection risk is primarily from fecal contamination of the environment due to the virus's ability to survive many months in the environment. Neighbors and family members with dogs should be notified of infected animals so that they can ensure that their dogs are vaccinated or tested for immunity. Vaccine will take up to 2 weeks to reach effective levels of immunity, the contagious individual should remain in quarantine until other animals are protected.
Treatment
Survival rate depends on how quickly CPV is diagnosed, the age of the animal and how aggressive the treatment is. Treatment for severe cases that are not caught early usually involves extensive hospitalization, due to the severe dehydration and damage to the intestines and bone marrow. A CPV test should be given as early as possible if CPV is suspected in order to begin early treatment and increase survival rate if the disease is found.
Treatment ideally consists of crystalloid IV fluids and/or colloids, antinausea injections (antiemetics) such as metoclopramide, dolasetron, ondansetron and prochlorperazine, and antibiotic injections such as cefoxitin, metronidazole, timentin, or enrofloxacin. IV fluids are administered and antinausea and antibiotic injections are given subcutaneously, intramuscularly, or intravenously. The fluids are typically a mix of a sterile, balanced electrolyte solution, with an appropriate amount of B-complex vitamins, dextrose and potassium chloride. Analgesic medications such as buprenorphine are also used to counteract the intestinal discomfort caused by frequent bouts of diarrhea.
In addition to fluids given to achieve adequate rehydration, each time the puppy vomits or has diarrhea in a significant quantity, an equal amount of fluid is administered intravenously. The fluid requirements of a patient are determined by their body weight, weight changes over time, degree of dehydration at presentation and surface area. The hydration status is originally determined by assessment of clinical factors like tacky mucous membranes, concentration of the urine, sunken eyes, poor skin elasticity and bloodtests.
A blood plasma transfusion from a donor dog that has already survived CPV is sometimes used to provide passive immunity to the sick dog. Some veterinarians keep these dogs on site, or have frozen serum available. There have been no controlled studies regarding this treatment. Additionally, fresh frozen plasma and human albumin transfusions can help replace the extreme protein losses seen in severe cases and help assure adequate tissue healing.
Once the dog can keep fluids down, the IV fluids are gradually discontinued, and very bland food slowly introduced. Oral antibiotics are administered for a number of days depending on the white blood cell count and the patient's ability to fight off secondary infection. A puppy with minimal symptoms can recover in 2 or 3 days if the IV fluids are begun as soon as symptoms are noticed and the CPV test confirms the diagnosis. However, even with hospitalization, there is no guarantee that the dog will survive.
Unconventional treatments
There is no specific antiviral treatment for CPV. However, there have been anecdotal reports of oseltamivir (Tamiflu) reducing disease severity and hospitalization time in canine parvovirus infection. The drug may limit the ability of the virus to invade the crypt cells of the small intestine and decrease gastrointestinal bacteria colonization and toxin production.[29] There is also anecdotal evidence suggesting that colloidal silver is effective at treating CPV although currently regulatory authorities are discouraging its use due to potential toxicity issues and lack of demonstrated efficacy. Lastly, recombinant feline interferon omega (rFeIFN-w), produced in silkworm larvae using a baculovirus vector, has been demonstrated by multiple studies to be an effective treatment.
CPV2 affects dogs, wolves, foxes, and other canids. CPV2a and CPV2b have been isolated from a small percentage of symptomatic cats and is more common than feline panleukopenia in big cats.
Previously it has been thought that the virus does not undergo cross species infection. However studies in Vietnam have shown that CPV2 can undergo minor antigenic shift and natural mutation to infect felids. Analyses of feline parvovirus (FPV) isolates in Vietnam and Taiwan revealed that more than 80% of the isolates were of the canine parvovirus type, rather than feline panleukopenia virus (FPLV).[13] CPV2 may spread to cats easier than dogs and undergo faster rates of mutation within that species. The virus does not transmit to birds, or humans , but it can be spread by them when a bird comes in contact with feces and then the dog's environment, or when a cat goes to the groomers and returns with an exposed pet carrier.
Variants
There are variants of CPV type 2 called CPV-2a, CPV-2b and CPV-2c. The antigenic patterns of 2a and 2b are quite similar to the original CPV type 2. Variant 2c however has a unique pattern of antigenicity. This has led to claims of ineffective vaccination of dogs, but studies have shown that the existing CPV vaccines based on CPV type 2b, provide adequate levels of protection against CPV type 2c. However, there are reports that outdated vaccines based on the old CPV-type 2 may not afford sufficient cross-protection against the type 2c variant.
Pathophysiology
There are two forms of CPV2: intestinal and cardiac. Puppies are most susceptible, but more than 80 percent of adult dogs show no symptoms. With severe disease, dogs can die within 48 to 72 hours without treatment by fluids and antibiotics. In the more common, less severe form, mortality is about 10 percent. Certain breeds, such as Rottweilers, Doberman Pinschers, and Pit bull terriers as well as other black and tan colored dogs may be more susceptible to CPV2. Along with age and breed, factors such as a stressful environment, concurrent infections with bacteria, parasites, and canine coronavirus increase a dog's risk of severe infection. Dogs who catch Parvovirus usually die from the dehydration it causes or secondary infection rather than the virus itself.
Intestinal form
Dogs become infected through oral contact with CPV2 in feces, infected soil, or fomites that carry the virus. Following ingestion, the virus replicates in the lymphoid tissue in the throat, and then spreads to the bloodstream. From there, the virus attacks rapidly dividing cells, notably those in the lymph nodes, intestinal crypts, and the bone marrow. There is depletion of lymphocytes in lymph nodes and necrosis and destruction of the intestinal crypts. Anaerobic bacteria that normally reside in the intestines can then cross into the bloodstream, a process known as translocation, and cause sepsis. The most common bacteria involved in severe cases are Clostridia, Campylobacter and salmonellaspecies. This can lead to a syndrome known as Systemic inflammatory response syndrome(SIRS). SIRS leads to a range of complications such as hypercoagulability of the blood, endotoxaemia and acute respiratory distress syndrome(ARDS). Bacterial Myocarditis has also been reported secondarily to sepsis. Dogs with CPV are at risk of intussusception, a condition where part of the intestine prolapses into another part. Three to four days following infection, the virus is shed in the feces for up to three weeks, and the dog may remain an asymptomatic carrier and shed the virus periodically. The virus is usually more deadly when infested with worms or other intestinal parasites.
Cardiac form
This form is less common and affects puppies infected in the uterus or shortly after birth until about 8 weeks of age. The virus attacks the heart muscle and the puppy often dies suddenly or after a brief period of breathing difficulty. On the microscopic level, there are many points of necrosis of the heart muscle that are associated with mononuclear cellular infiltration. The formation of excess fibrous tissue (fibrosis) is often evident in surviving dogs. Myofibers are the site of viral replication within cells. The disease may or may not be accompanied with the signs and symptoms of the intestinal form. However, this form is now rarely seen due to widespread vaccination of breeding dogs.
Even less frequently, the disease may also lead to a generalized infection in neonates and cause lesions and viral replication and attack in other tissues other than the gastrointestinal tissues and heart, but also brain, liver, lungs, kidneys, and adrenal cortex. The lining of the blood vessels are also severely affected, which lead the lesions in this region to hemorrhage.
Infection in the uterus
This type of infection can occur when a pregnant female dog is infected with CPV2. The adult may develop immunity with little or no clinical signs of disease. The virus may have already crossed the placenta to infect the foetus. This can lead to several abnormalities. In severe cases the pups can be still born or born mummified, in mild to moderate cases the pups can be born with neurological abnormalities such as cerebellar hypoplasia.
Signs and symptoms
Dogs that develop the disease show symptoms of the illness within 5 to 10 days. The symptoms include lethargy, vomiting, fever, and diarrhea (usually bloody). Diarrhea and vomiting result in dehydration and secondary infections can set in. Due to dehydration, the dog's electrolyte balance can become critically affected. Because the normal intestinal lining is also compromised, blood and protein leak into the intestines leading to anemia and loss of protein, and endotoxins escaping into the bloodstream, causing endotoxemia. Dogs have a distinctive odor in the later stages of the infection. The white blood cell level falls, further weakening the dog. Any or all of these factors can lead to shock and death.
Diagnosis
Diagnosis is made through detection of CPV2 in the feces by either an EIA or a hemagglutination test, or by electron microscopy. PCR has become available to diagnose CPV2, and can be used later in the disease when potentially less virus is being shed in the feces that may not be detectable by EIA. Clinically, the intestinal form of the infection can sometimes be confused with coronavirus or other forms of enteritis. Parvovirus, however, is more serious and the presence of bloody diarrhea, a low white blood cell count, and necrosis of the intestinal lining also point more towards parvovirus, especially in an unvaccinated dog. The cardiac form is typically easier to diagnose because the symptoms are distinct.
Prevention and decontamination
Prevention is the only way to ensure that a puppy or dog remains healthy since the disease is extremely virulent and contagious. The virus is extremely hardy and has been found to survive in feces and other organic material such as soil for over a year. It survives extremely cold and hot temperatures. The only household disinfectant that kills the virus is bleach.
Weaning puppies can be vaccinated with a modified live virus low passage high titer vaccine at 6 weeks of age, then every 3 to 4 weeks until 15 or 16 weeks. Puppies are initially protected through passive immunity derived from the mother. These maternal antibodies wear off before the puppy's immune system is mature enough to fight off CPV2 infection. Maternal antibodies also interfere with vaccination for CPV2 and can cause vaccine failure. Thus puppies are generally vaccinated in a series of shots, extending from the earliest time that the immunity derived from the mother wears off until after that passive immunity is definitely gone. Older puppies (16 weeks or older) are given 3 vaccinations 3 to 4 weeks apart. The duration of immunity of vaccines for CPV2 has been tested for all major vaccine manufacturers in the United States and has been found to be at least three years after the initial puppy series and a booster 1 year later.
A dog that successfully recovers from CPV2 sheds virus for a few days. Ongoing infection risk is primarily from fecal contamination of the environment due to the virus's ability to survive many months in the environment. Neighbors and family members with dogs should be notified of infected animals so that they can ensure that their dogs are vaccinated or tested for immunity. Vaccine will take up to 2 weeks to reach effective levels of immunity, the contagious individual should remain in quarantine until other animals are protected.
Treatment
Survival rate depends on how quickly CPV is diagnosed, the age of the animal and how aggressive the treatment is. Treatment for severe cases that are not caught early usually involves extensive hospitalization, due to the severe dehydration and damage to the intestines and bone marrow. A CPV test should be given as early as possible if CPV is suspected in order to begin early treatment and increase survival rate if the disease is found.
Treatment ideally consists of crystalloid IV fluids and/or colloids, antinausea injections (antiemetics) such as metoclopramide, dolasetron, ondansetron and prochlorperazine, and antibiotic injections such as cefoxitin, metronidazole, timentin, or enrofloxacin. IV fluids are administered and antinausea and antibiotic injections are given subcutaneously, intramuscularly, or intravenously. The fluids are typically a mix of a sterile, balanced electrolyte solution, with an appropriate amount of B-complex vitamins, dextrose and potassium chloride. Analgesic medications such as buprenorphine are also used to counteract the intestinal discomfort caused by frequent bouts of diarrhea.
In addition to fluids given to achieve adequate rehydration, each time the puppy vomits or has diarrhea in a significant quantity, an equal amount of fluid is administered intravenously. The fluid requirements of a patient are determined by their body weight, weight changes over time, degree of dehydration at presentation and surface area. The hydration status is originally determined by assessment of clinical factors like tacky mucous membranes, concentration of the urine, sunken eyes, poor skin elasticity and bloodtests.
A blood plasma transfusion from a donor dog that has already survived CPV is sometimes used to provide passive immunity to the sick dog. Some veterinarians keep these dogs on site, or have frozen serum available. There have been no controlled studies regarding this treatment. Additionally, fresh frozen plasma and human albumin transfusions can help replace the extreme protein losses seen in severe cases and help assure adequate tissue healing.
Once the dog can keep fluids down, the IV fluids are gradually discontinued, and very bland food slowly introduced. Oral antibiotics are administered for a number of days depending on the white blood cell count and the patient's ability to fight off secondary infection. A puppy with minimal symptoms can recover in 2 or 3 days if the IV fluids are begun as soon as symptoms are noticed and the CPV test confirms the diagnosis. However, even with hospitalization, there is no guarantee that the dog will survive.
Unconventional treatments
There is no specific antiviral treatment for CPV. However, there have been anecdotal reports of oseltamivir (Tamiflu) reducing disease severity and hospitalization time in canine parvovirus infection. The drug may limit the ability of the virus to invade the crypt cells of the small intestine and decrease gastrointestinal bacteria colonization and toxin production.[29] There is also anecdotal evidence suggesting that colloidal silver is effective at treating CPV although currently regulatory authorities are discouraging its use due to potential toxicity issues and lack of demonstrated efficacy. Lastly, recombinant feline interferon omega (rFeIFN-w), produced in silkworm larvae using a baculovirus vector, has been demonstrated by multiple studies to be an effective treatment.
 | Printable Version |
 |
The material and information on this website, including any merchandise, information or service provided through this website, is provided "as is"
with all faults and without warranty of any kind from the Furry Critter Network, expressed or implied. In no event shall the Furry Critter Network be
liable for any direct damages, special, incidental or consequential damages, lost profits, or any indirect damages arising from the use or inability
to use this website, even if the Furry Critter Network has been informed of the possibility thereof.
